Patents Represented by Attorney, Agent or Law Firm Michael A. Sanzo
-
Patent number: 7195748Abstract: The invention relates to a process for the production of hydrogen peroxide by the anthraquinone process, comprising a hydrogenation stage, an oxidation stage and an extraction stage. According to the invention, catalytic hydrogenation of anthraquinone derivatives dissolved in a working solution is carried out in the presence of added molecular oxygen. Per mol hydrogen, 0.1 to 10 mmol oxygen is preferably introduced into the hydrogenation stage with the hydrogenating gas, in mixture with an inert gas and/or dissolved and/or dispersed in the working solution. This increases the residence time of the catalyst.Type: GrantFiled: March 4, 2003Date of Patent: March 27, 2007Assignee: Degussa AGInventors: Bernd Jaeger, Thomas Haas, Jürgen Glenneberg, Jürgen Grunert
-
Patent number: 6821751Abstract: The present invention is directed to DNA elements that enhance cellular gene expression in response to anaerobic growth or the presence of certain inducing agents. The enhancer element may be incorporated into expression vectors and used to increase the production of recombinant proteins.Type: GrantFiled: January 10, 2002Date of Patent: November 23, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventors: Mark Alan Goldberg, Michael Vasconcelles, Yide Jiang
-
Patent number: 6800749Abstract: The present invention is directed to a novel neurotensin-like receptor expressed in the central nervous system of humans. The invention encompasses the receptor protein as well as nucleic acids encoding the protein. In addition, the invention is directed to methods and compositions which utilize the receptor.Type: GrantFiled: July 1, 1999Date of Patent: October 5, 2004Assignee: AstraZeneca Canada Inc.Inventors: Sultan Ahmad, Jack Cao, Dajan O'Donnell, Philippe Walker
-
Patent number: 6784210Abstract: The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.Type: GrantFiled: December 12, 2002Date of Patent: August 31, 2004Assignee: AstraZeneca ABInventors: Keith Fagnou, Mark Lautens
-
Patent number: 6784181Abstract: The present invention is directed to a compound of general formula (I), wherein R1 is selected from phenyl, pyridinyl, thiophenyl, furanyl, imidazolyl; each phenyl ring and heteroaromatic ring optionally and independently being further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo, as well as their pharmaceutically acceptable salts. The invention includes pharmaceutical compositions comprising these compounds and the use of the compounds in therapy, in particular in the management of pain.Type: GrantFiled: October 21, 2002Date of Patent: August 31, 2004Assignee: AstraZeneca ABInventors: William Brown, Christopher Walpole, Niklas Plobeck
-
Patent number: 6777561Abstract: Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.Type: GrantFiled: June 1, 2000Date of Patent: August 17, 2004Assignee: AstraZeneca Canada Inc.Inventors: Daniel Delorme, Vlad Gregor, Edward Roberts, Eric Sun
-
Patent number: 6774132Abstract: The present invention relates to certain spirooxindole derivatives and to pharmaceutically acceptable salts thereof, which exhibit good analgesic properties and are effective in the treatment of chronic pain. The derivatives have the structure of formula I: wherein: Ar is benzene or pyridine; X is NHCO—; —CONH—; or —NH—SO2—; Y is a single bond; and Z is —CH═CHCH2.Type: GrantFiled: October 27, 2000Date of Patent: August 10, 2004Assignee: AstraZeneca ABInventors: Alf Claesson, Britt-Marie Swahn, Odd-Geir Berge
-
Patent number: 6756387Abstract: Compounds of general formula I R1 is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, triazolyl and thiazolyl; where each R1 phenyl ring and R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.Type: GrantFiled: January 16, 2003Date of Patent: June 29, 2004Assignee: AstraZeneca ABInventors: William Brown, Christopher Walpole, Zhongyong Wei
-
Patent number: 6753335Abstract: Compounds of general formula I R1 is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, and triazolyl; where each R1 phenyl ring and R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.Type: GrantFiled: January 21, 2003Date of Patent: June 22, 2004Assignee: AstraZeneca ABInventors: William Brown, Christopher Walpole, Zhongyong Wei
-
Patent number: 6722062Abstract: The present invention is directed to a method for purifying polysaccharides capable of inducing the production of high titers of opsonic antibodies that kill strains of enterococcal bacteria. In addition, the invention is directed to the antigens produced by this purification method and to vaccines which utilize such antigens.Type: GrantFiled: March 11, 2002Date of Patent: April 20, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventors: Gerald B. Pier, Johannes Huebner, Ying Wang, Lawrence Madoff
-
Patent number: 6710025Abstract: The present invention is directed to therapeutic methods that are based upon an ability to modulate cellular contraction. This is accomplished by administering agents that either inhibit or induce the activity of alpha-smooth muscle actin.Type: GrantFiled: May 23, 2000Date of Patent: March 23, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventor: Myron Spector
-
Patent number: 6710179Abstract: Compounds of general formula (I) wherein m is 0 or 1, and n is 1 or 2; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.Type: GrantFiled: April 15, 2002Date of Patent: March 23, 2004Assignee: AstraZeneca Canada Inc.Inventors: Benjamin Pelcman, Edward Roberts
-
Patent number: 6709651Abstract: The present invention is directed to methods of treating a wide variety of diseases, disorders and conditions characterized by excessive activity of substance P. The treatment involves administering peptidases that recognize and selectively cleave polypeptides at Xaa-Pro sequences.Type: GrantFiled: July 3, 2001Date of Patent: March 23, 2004Assignee: B.M.R.A. Corporation B.V.Inventors: Eric Grouzmann, Jean-Silvain Lacroix, Michel Monod
-
Patent number: 6703483Abstract: Compounds of the formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, particular in the management of pain, and more particularly in the management of pain during labor.Type: GrantFiled: June 9, 2000Date of Patent: March 9, 2004Assignee: Cornell Research Foundation, Inc.Inventor: Peter Schiller
-
Patent number: 6696287Abstract: The present invention is directed to an apparatus that can be used for co-culturing bacteria and eukaryotic cells. The apparatus allows the bacteria to be grown under steady state conditions and then perfused over the eukaryotic cells. The invention also includes a variety of methods for studying the attachment and invasion of host eukaryotic cells by bacteria.Type: GrantFiled: March 19, 2002Date of Patent: February 24, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventors: Lawrence C. Paoletti, Gennady Malin
-
Patent number: 6696447Abstract: The present application describes compounds of general formula I where R1 is selected from any one of pyridinyl, thienyl, furanyl, imidazolyl, and triazolyl; and where each R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the heteroaromatic ring may take place in any position on the ring system. The invention also includes enantiomers, salts and pharmaceutical compositions containing the compounds. The compounds may be used in treating patients for pain.Type: GrantFiled: September 27, 2002Date of Patent: February 24, 2004Assignee: AstraZeneca ABInventors: William Brown, Niklas Plobeck, Christopher Walpole
-
Patent number: 6696257Abstract: The present invention is directed to novel G protein-coupled receptors that are found predominantly in the dorsal root ganglia. The invention encompasses both the receptor proteins as well as nucleic acids encoding the proteins. In addition, the present invention is directed to methods and compositions which utilize the receptors.Type: GrantFiled: March 3, 1999Date of Patent: February 24, 2004Assignee: National Research Council of CanadaInventors: Sultan Ahmad, Denis Banville, Yves Fortin, Paola Lembo, Dajan O'Donnell, Shi-Hsiang Shen
-
Patent number: 6693117Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.Type: GrantFiled: August 19, 2002Date of Patent: February 17, 2004Assignee: AstraZeneca Canada Inc.Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
-
Patent number: 6680318Abstract: The present application is directed to compounds having the general formula: and to the use of these compounds in therapeutic methods.Type: GrantFiled: October 21, 2002Date of Patent: January 20, 2004Assignee: AstraZeneca ABInventors: William Brown, Christopher Walpole, Niklas Plobeck
-
Patent number: 6680321Abstract: Compounds of the formula (I) as well as their pharmaceutically acceptable salts, and pharmaceutical compositions comprising the novel compounds. The novel compounds of the formula (I) are useful in the management of pain.Type: GrantFiled: August 2, 2000Date of Patent: January 20, 2004Assignee: AstraZeneca Canada, Inc.Inventors: Edward Roberts, Niklas Plobeck, Claes Wahlestedt